Rifaximin

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Visceral Hypersensitivity

Conditions

Visceral Hypersensitivity, Irritable Bowel Syndrome

Trial Timeline

Jul 1, 2018 → Nov 19, 2021

NCT ID

NCT03462966

About Rifaximin

Rifaximin is a phase 2 stage product being developed by Bausch Health for Visceral Hypersensitivity. The current trial status is terminated. This product is registered under clinical trial identifier NCT03462966. Target conditions include Visceral Hypersensitivity, Irritable Bowel Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03818672	Approved	Terminated	Jan 29, 2019	Feb 2, 2020	Severe Hepatic Impairment
NCT03462966	Phase 2	Terminated	Jul 1, 2018	Nov 19, 2021	Visceral Hypersensitivity
NCT01654939	Approved	Withdrawn	Oct 1, 2012	Sep 1, 2015	HIV
NCT01542541	Pre-clinical	Completed	Jul 1, 2011	Oct 1, 2012	Intestinal FDG Uptake
NCT00743912	Phase 1	Completed	Sep 1, 2008	Nov 1, 2008	Pharmacokinetic
NCT00686920	Phase 3	Completed	Mar 7, 2007	Dec 8, 2010	Hepatic Encephalopathy
NCT00328380	Phase 3	Completed	Dec 1, 2005	Sep 1, 2008	Diarrhea
NCT00269412	Phase 2	Completed	Dec 1, 2005	Sep 1, 2008	Irritable Bowel Syndrome
NCT00259155	Phase 2	Completed	Jul 1, 2003	Jan 1, 2007	Irritable Bowel Syndrome
NCT00098384	Phase 2	Completed	Jun 1, 2003	Sep 1, 2003	Diarrhea

Competing Products

5 competing products in Visceral Hypersensitivity

See all competitors

Product	Company	Stage	Hype Score
Amphotericin B Liposome + AmBisome (Amphotericin B) Liposome	Aurobindo Pharma	Phase 1	33
LXE408 + AmBisome®	Novartis	Phase 2	52
LXE408 + sodium stibogluconate + Paromomycin	Novartis	Phase 2	52
Liposomal amphotericin B (AmBisome®) and sodium stibogluconate + Liposomal amphotericin B + miltefosine + Miltefosine	Gilead Sciences	Phase 2	51
Liraglutide + Placebo	Novo Nordisk	Approved	84

Other Products from Bausch Health

nabiloneApproved

High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foamApproved

benzoyl peroxide wash + Tretinoin gelApproved

Adapalene Gel + Tretinoin GelApproved

Omeprazole/sodium bicarbonateApproved